by Admin | Mar 18, 2026 | Regulatory Updates
MHRA’s Safety Roundup: February 2026 describes itself as a summary of the latest safety advice for medicines and medical device users. The roundup highlights recent issues including semaglutide-associated NAION and falsified Mounjaro pens, giving readers a concise...
by Admin | Mar 18, 2026 | Safety Signals
MHRA says non-arteritic anterior ischemic optic neuropathy (NAION), a condition that can cause sudden vision deterioration, has been very rarely reported in association with semaglutide used for type 2 diabetes, weight management, and cardiovascular risk reduction....
by Admin | Mar 18, 2026 | Safety Signals
EMA’s Pharmacovigilance Risk Assessment Committee said it completed its review of a safety signal involving aseptic meningitis with Ixchiq, the live attenuated chikungunya vaccine, and recommended updating the vaccine’s product information to reflect the most recent...
by Admin | Mar 18, 2026 | Regulatory Updates
FDA has required an additional MRI between the 2nd and 3rd Leqembi infusions to help detect amyloid-related imaging abnormalities with edema, or ARIA-E, earlier in treatment. The agency said ARIA-E is often asymptomatic but can also involve serious and...
by Admin | Mar 18, 2026 | Careers, News
A growing wave of concern is emerging across parts of the pharmaceutical and drug safety industry over alleged proxy interviews, false professional representation, and unethical third-party involvement in pharmacovigilance hiring. Across regulated safety functions,...
